Results 61 to 70 of about 1,580 (184)

A Systematic Review and Meta-analysis of Efficacy and Safety of Mavacamten for the Treatment of Hypertrophic Cardiomyopathy

Reviews in Cardiovascular Medicine
Background: Hypertrophic cardiomyopathy (HCM) is a common hereditary cardiomyopathy. Mavacamten, a first-in-class cardiac myosin inhibitor, is considered to be a specific drug for the treatment of HCM.
Li Zheng, Xiaotong Gu, Yumiao Chen, Deping Liu   +3 more
doaj   +1 more source

CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 329-347, February 2026.
Clopidogrel, an antiplatelet agent, is currently licensed in the United Kingdom for the prevention and treatment of atherothrombotic events in cerebrovascular disease, coronary artery disease and peripheral arterial disease. Clopidogrel requires metabolic activation by the cytochrome P450 enzyme CYP2C19 to be effective.
Cinzia Dello Russo, Iain Frater, Rebecca Kuruvilla, Stefanie Lip, Hannah O'Neill, Kerry Burke, Vicky Chaplin, Alexander S. F. Doney, Salim Elyas, Nicholas Greaves, Sophie Harding, David Hargroves, Judith Hayward, Dyfrig A. Hughes, Tom A. T. Hughes, Sree Kondapally, Patrick Mok, Aaron Peace, Imran Rafi, Simon Ray, Vicky Stinton, Luigi Venetucci, Munir Pirmohamed   +22 more
wiley   +1 more source

Toward a More accurate, Evidence‐Based Classification of CYP Inhibitors: A Critical Appraisal of Current Systems

Clinical Pharmacology &Therapeutics, Volume 119, Issue 1, Page 30-32, January 2026.
In this issue of CPT, Malavé et al. deliver a comprehensive reassessment of CYP2C19 inhibitor classifications through a systematic review of clinical drug–drug interaction (DDI) studies. While their findings bring clarity to specific discrepancies, this commentary explores the origins of such inconsistencies, particularly focusing on methodological ...
Janne T. Backman
wiley   +1 more source

Mavacamten stabilizes the auto-inhibited state of two-headed cardiac myosin

, 2018
We used transient biochemical and structural kinetics to elucidate the molecular mechanism of mavacamten, an allosteric cardiac myosin inhibitor and prospective treatment for hypertrophic cardiomyopathy.
John A. Rohde, David D. Thomas, Joseph M. Muretta   +2 more
core   +1 more source

Recommendation of mavacamten posology by model‐based analyses in adults with obstructive hypertrophic cardiomyopathy

CPT: Pharmacometrics & Systems Pharmacology
Mavacamten is the first cardiac myosin inhibitor approved by the US Food and Drug Administration for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
Samira Merali, David H. Salinger, Maria Palmisano, Amy J. Sehnert, Neelima Thanneer, Hyunmoon Back, Julie D. Seroogy, Daniel D. Gretler, Amit Roy, Vidya Perera   +9 more
doaj   +1 more source

Long‐Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER‐OLE Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background The phase 2 PIONEER‐HCM (Phase 2 Open‐label Pilot Study Evaluating Mavacamten in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction) study showed that mavacamten improved left ventricular ...
Ahmad Masri, Steven J. Lester, John C. Stendahl, Sheila M. Hegde, Amy J. Sehnert, Ganesh Balaratnam, Ashish Shah, Shawna Fox, Andrew Wang   +8 more
doaj   +1 more source

French‐Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Gene Panel Analysis Through Genotyping or Sequencing in Pharmacogenetics

Fundamental &Clinical Pharmacology, Volume 40, Issue 1, January 2026.
ABSTRACT Background The implementation of pharmacogenetics in clinical practice increasingly relies on multigene panels. Objectives The objective of this study is to develop harmonized recommendations for the design and analytical implementation of multigene pharmacogenetic panels, defining clinically relevant genes and associated regions of interest ...
Nicolas Picard, Estelle Ayme‐Dietrich, Sylvie Quaranta, Tiphaine Adam‐De‐Beaumais, Abd El Kader Ait Tayeb, Hugo Alarcan, Dorra Amor, David Barthelemy, Mouna Ben Sassi, Séverine Cunat, Mouna Daldoul, Hervé Delacour, Marie‐Christine Etienne‐Grimaldi, Xavier Fonrose, Benjamin Hennart, Louis Lebreton, Stephanie Malard, Céline Narjoz, Asma Omezzine, Nicolas Pallet, Léa Payen, Jeanne Petit, Fabienne Thomas, Sameh Trabelsi, Camille Tron, Céline Verstuyft, Paul Vilquin, Jean‐Christophe Boyer, Vincent Haufroid, French‐Speaking Network of Pharmacogenetics (RNPGx)   +29 more
wiley   +1 more source

Mavacamten for hypertrophic obstructive cardiomyopathy [PDF]

The Lancet, 2021
Eduard, Quintana, Pietro, Bajona, Patrick O, Myers   +2 more
openaire   +2 more sources

Unveiling Mid‐Cavity Obstruction in Hypertrophic Cardiomyopathy: A Case‐Based Approach

Case Reports in Cardiology, Volume 2026, Issue 1, 2026.
Background Hypertrophic cardiomyopathy (HCM) is a genetic disorder causing myocardial hypertrophy, sometimes leading to mid‐cavity obstruction (MCO), which can be underdiagnosed based solely on noninvasive imaging. Case summary A 52‐year‐old male with exertional dyspnea and chest pain showed apical hypertrophy on echocardiography, with a mid‐cavity ...
Anass Maaroufi, Nicolas Verheyen, Judit Andreka, Gabor G. Toth, Stefan Harb, Michael Lichtenauer   +5 more
wiley   +1 more source

Precision Negative Inotropy: The Rise of Cardiac Myosin Inhibitors in HCM

Journal of Education, Health and Sport
Background: Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, marked by left-ventricular hypertrophy, dynamic outflow obstruction in many patients, diastolic dysfunction, and elevated risks of atrial fibrillation and heart ...
Katarzyna Skibicka, Tomasz Skibicki, Weronika Wesołowska, Robert Bujak   +3 more
doaj   +1 more source